Halozyme Inc. - HALO Debts to Book Capitalization

Corporate emblem and logo of Halozyme Therapeutics, Inc. (HALO)

Halozyme Therapeutics (HALO) is developing B2B partnerships with pharmaceutical behemoths, attracting leading biotechnologists to refine drug delivery systems. The debt-to-equity ratio confirms a financial strategy where 14.85 serves as the current parameter value. The licensing model guarantees stable royalties without production risks, while operations in the US and EU markets provide immunity to geopolitical shocks.

Halozyme Therapeutics - HALO Debts to Book Value (period 07/04/2022 - 10/29/2026)

Comprehensive metric breakdowns and analytics for Halozyme Therapeutics, Inc. (HALO)

- market price and analyst price targets:
Price Chart Halozyme Therapeutics|HALO - Broker Consensus Forecast
- issuer market value details:
Market Capitalization Halozyme Corp|HALO - Real Price to Acquire Entire Company
- issuer book value statistics:
Book Value per Share Halozyme|HALO - Total Stockholders' Equity|Market Value to Book Value Ratio halozyme.com|HALO - Aggregate Asset Value
- debt level and financial liquidity data:
Total Debt to Equity Ratio Halozyme Therapeutics|HALO - Long-Term Debt to Capital Coefficient|Short-Term Debt to Capital Halozyme Inc.|HALO - Company Total Debt|Debt to Book Value Halozyme Corp|HALO - Company Long-Term Debts|Company Short-Term Debt Halozyme|Quick Ratio halozyme.com
- financial results and valuation multiples details:
HALO - Company Net Income
Analysis of all company metrics:Halozyme Therapeutics (HALO)
Manufactured products of Halozyme Therapeutics, Inc.

This indicator determines the ratio of borrowed funds to net asset value, allowing investors to assess the level of financial leverage and the balance sheet's resilience to market shocks. Analyzing the debt-to-market cap profile of Halozyme Therapeutics (HALO) on GURU.Markets reveals how the high margins from ENHANZE technology royalties minimize the company's reliance on external loans, thereby strengthening the protection of investment capital.

Competitors of Halozyme Therapeutics

Debt to Book Capitalization Ratio BeiGene Ltd ONC|RVMD: Debt to Book Value Ratio|Ascentage Pharma - Debts to Book Capitalization|CG Oncology Inc (CGON) - Debt to Book Value|URGN: Debts to Book Capitalization|Debts to Book Value Bicara Corp (BCAX)|Debt to Book Capitalization Ratio Personalis, Inc.|ERAS: Debt to Net Assets Ratio|Debt to Book Value DCTH (Delcath Systems)|YMAB (Y-mAbs Therapeutics Inc) - Debt to Net Assets Ratio|Debts to Book Capitalization AURA (Aura Bio)|CADL - Debt to Book Value|ARAY: Debt to Book Value|SLS - Debts to Book Capitalization|Actuate Therapeutics (ACTU) - Debt to Book Capitalization Ratio|Citius Oncology Inc. - Debt to Net Assets Ratio|HURA (TuHURA Biosciences Inc.) - Debts to Book Capitalization|Debts to Book Value Protara Tx TARA|Debts to Book Capitalization FATE|WHWK (aadibio.com) - Debt to Net Assets Ratio|Debts to Book Capitalization TCRX (TScan Therapeutics, Inc.)|Debts to Book Capitalization Champions Oncology Inc CSBR|XBIT - Debt to Book Capitalization Ratio|CVM: Debt to Book Capitalization Ratio|OS Therapies Incorporated (OSTX) - Debt to Book Capitalization Ratio|Debts to Book Value radiopharmtheranostics.com (RADX)|Debt to Book Value ARTV|Adlai Nortye Limited - Debts to Book Capitalization Ratio|Debt to Book Value VERU (Veru Pharma)|TPST - Debts to Book Value|Debt to Book Capitalization Ratio Xilio Therapeutics XLO|RENB - Debt to Book Value|Mural Bio - Debts to Book Capitalization|Debts to Book Value Kairos Pharma Ltd|OKUR (onkuretherapeutics.com) - Debt to Book Value|CytoMed Therapeutics Limited - Debt to Net Assets Ratio|Debt to Book Value CRIS|APLM (Apollomics Corp) - Debt to Book Capital|Debts to Book Capitalization THAR|ADVB (advanbiomed.com) - Debt to Net Assets Ratio|Debts to Book Capitalization GNPX (Genprex, Inc)|Calidi Biotherapeutics Inc. (CLDI) - Debts to Book Value|SBFM - Debt to Book Capitalization Ratio|Debt to Net Assets Ratio XBIO (Xenetic Biosciences)|SLRX: Debts to Book Capitalization|Purple Biotech Ltd (PPBT) - Debts to Book Capitalization|Debt to Book Capitalization Ratio American Oncology Network Inc|BeiGene Ltd - Debts to Book Capitalization Ratio|Debts to Book Capitalization CKPT|ELEV - Debts to Book Value|iCAD - Debt to Book Value|Debts to Book Capitalization Ikena Oncology Inc. IKNA|NTBL: Debt to Book Value|Viracta Therapeutics - Debt to Book Capital|MOR: Debts to Book Capitalization|NAYA - Debts to Net Assets|AAPGV (Ascentage Pharma) - Debts to Book Capitalization